This study is a multi-site, Phase 1b, open-label study of orally administered NDX-3315 and esophageal imaging in healthy participants and participants with EoE.~Study details include:~The study duration or period will be up to around 10 weeks.~Participants will receive either one or two doses of NDX-3315 depending on their assigned regimen arm. EoE participants will receive two doses; healthy participants will receive one dose.~The visit frequency will be three site visits for healthy participants and four site visits for EoE participants followed by one follow-up phone call visit within the study period.
An open-label phase 1b study to assess the safety and exploratory diagnostic performance of the oral radiopharmaceutical agent NDX-3315 in healthy participants and patients with eosinophilic esophagitis (EoE).